(19)
(11) EP 3 846 799 A1

(12)

(43) Date of publication:
14.07.2021 Bulletin 2021/28

(21) Application number: 19745113.1

(22) Date of filing: 24.07.2019
(51) International Patent Classification (IPC): 
A61K 31/395(2006.01)
C12N 15/113(2010.01)
A61P 35/00(2006.01)
 C07K 16/28(2006.01)
A61K 39/395(2006.01)
(86) International application number:
PCT/EP2019/069908
(87) International publication number:
WO 2020/020942 (30.01.2020 Gazette 2020/05)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 24.07.2018 EP 18382555
08.04.2019 EP 19382257

(71) Applicant: Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO)
28029 Madrid (ES)

(72) Inventors:
  • BARBACID, Mariano
    28029 Madrid (ES)
  • GUERRA, Carmen
    28029 Madrid (ES)
  • BLASCO, María Teresa
    28029 Madrid (ES)
  • NAVAS, Carolina
    28029 Madrid (ES)

(74) Representative: Elzaburu S.L.P. 
Miguel Angel 21, 2nd floor
28010 Madrid
28010 Madrid (ES)

   


(54) COMBINED THERAPY INHIBITING EXPRESSION, ACTIVITY AND/OR FUNCTION OF EPIDERMAL GROWTH FACTOR RECEPTOR AND C-RAF AGAINST CANCER